• Who We Are
  • Latest Updates
  • Community Voices
  • Alliance Resources
  • Preterm Birth Resources
  • Contact Us

Mothers deserve access to the best possible treatments to prevent preterm birth.

Who We Are

The Preterm Birth Prevention Alliance is a coalition of maternal and women’s health advocates who share a common concern about the state of preterm birth in the United States and the proposed market withdrawal of 17P, the only FDA- approved class of treatments to help prevent spontaneous, recurrent preterm birth. Formed in 2021 by the National Consumers League, we seek to improve preterm birth outcomes in the United States by maintaining access to safe, FDA-approved treatment options and advocating for more diverse medical research that adequately represents the experiences of women and newborns of color. Women of color need a seat at the table.

Our Members

Latest Updates

FDA Announces Hearing Date for 17P

June 14, 2022

The FDA has announced that it expects to hold a long-awaited hearing on the future of 17P on October 17-19, 2022. The virtual hearing will help decide the fate of 17P — the only FDA-approved class of medications that safely reduce the risk of spontaneous, recurrent preterm birth for moms who have already had a preterm baby.

The hearing will be held virtually and follow the agenda available here, on the public docket. The four hours dedicated for public comment over the 2.5-day hearing provides us with a unique opportunity — both as individual organizations and as a collective Alliance. We look forward to amplifying the diverse voices of mothers, babies, families, and advocates as we seek to highlight the need to improve preterm birth outcomes in the United States and address its disproportionate impact on women of color through continued access to FDA-approved treatment options.

We will update this with more information about providing testimony and participating in the hearing as it becomes available.

PBPA Commends HHS Funding to Support Maternal and Infant Health

September 30, 2021
The Preterm Birth Prevention Alliance (PBPA), a coalition of maternal and women’s health advocates dedicated to improving preterm birth outcomes in the United States and addressing its disproportionate impact on women of color…..Read More >

Preterm Birth Prevention Alliance Applauds FDA’s Granting of Hearing for the Only FDA-Approved Therapies to Reduce Recurrent Preterm Birth
August 26, 2021
The Preterm Birth Prevention Alliance, a coalition of maternal and women’s health advocates dedicated to improving preterm birth outcomes in the United States and addressing its disproportionate impact on….Read More >

PBPA meets with the office of Congresswoman Madeleine Dean (PA-4)
July 29, 2021
The PBPA had the opportunity to meet with Representative Dean’s office to discuss the importance of FDA-approved treatment options for women facing preterm birth.

PBPA meets with the White House Domestic Policy Council
July 20, 2021
The PBPA was honored to meet with the White House Domestic Policy Council to discuss maternal and infant health and health equity.

Leading patient advocates launch Preterm Birth Prevention Alliance to protect critical access to the sole FDA-approved class of therapies to reduce recurrent preterm birth
April 20, 2021
Today, the National Consumers League (NCL), along with a coalition of patient advocacy organizations dedicated to advancing the health of mothers and infants, announced the launch of the Preterm Birth Prevention Alliance….Read More >

Community Voices

 
PreviousNext

Candace Hurley
Founder and Executive Director
Sidelines High Risk Pregnancy Support

“We have thousands of women who have written to us, called us, in support of their use of 17P when they previously had preterm deliveries.”

Jamie Campos
Mom

“I believe the Makena injections and my dedicated group of doctors is what made all the difference and allowed me to deliver and at safe gestation.”

Jada Ledbetter, MPH
Program Manager, Maternal and Child Health
Black Women’s Health Imperative

“Prevention of preterm birth is imperative for Black birthing people and babies to both survive and prosper.”

Crystal McAuley
Coalition Director
Mom Congress

“The study on 17P must be replicated to include an accurate representative number of Black mothers in the United States.”

Alliance Resources

About the Alliance

The Preterm Birth Prevention Alliance (PBPA) formed as a coalition of organizations concerned about the state of preterm birth in the United States and its disproportionate impact on women of color. PBPA’s mission is to improve preterm birth outcomes in the United States by preserving access to safe, Food and Drug Administration (FDA) approved treatment options and advocating for more diverse medical research that adequately represents the experiences of women and newborns of color.
Read More >

Alliance Consensus Statement

The Preterm Birth Prevention Alliance (PBPA) is guided by a core set of principles to advocate for the health interests of at-risk pregnant women and their children. Check out our consensus statement on maintaining access to FDA-approved treatment to prevent spontaneous recurrent preterm birth.

Read More >

Diverse research for a diverse America: The value of equitable, real-world research

National Consumers League Executive Director, Sally Greenberg, shares her perspective on the important role that expanding diversity and representation in medical research can have on health outcomes, especially maternal health.
Read More >

Recognizing the Potential for Real-World Evidence in Maternal Health Infographics

The Preterm Birth Prevention Alliance believes that preterm birth and its disproportionate impact on women of color provide a key example of why we need representative research and Real-World Evidence on treatment efficacy across populations. Check out these infographics for perspectives from recent surveys among women and women’s health, obstetric and neonatal nurses.

Read more on the need for more research across diverse populations >
Read more on women’s perspectives on FDA-approved treatments >

Preterm Birth Resources

Evidence has shown that there may be an increased risk of preterm birth and pregnancy loss among pregnant women with COVID-19. Even aside from COVID risks, premature birth is a leading cause of infant death in the United States. It’s devastating for mothers and families and is very costly to the healthcare system.

 

Prematurity also has a significantly disproportionate impact on Black, Indigenous, and women of color. According to the March of Dimes, the preterm birth rate among Black American women is 50 percent higher than the rate among all other women.

 

Only one FDA-approved intervention currently exists to help pregnant women prevent a recurrent preterm birth. It is a prescription medicine called hydroxyprogesterone caproate, which is also known as “17P” or “17-OHPC.” 17P has played a significant role in the treatment of thousands of pregnant mothers and their babies as the only FDA-approved therapy to reduce the risk of recurrent preterm birth and help mothers carry their pregnancies to full-term—which is crucially important to the health of babies.

 

Recently, the FDA has proposed that 17P be pulled from the market in all forms—branded, generics, and compounded—and advocates are fighting to preserve this resource for women at risk for preterm birth.

Information on Preterm Birth

January 4, 2021

Preterm Labor and Premature Birth

Overview of Preterm Labor and Premature Birth from March of Dimes

November 16, 2020

2020 March of Dimes Report Card

Each November, during Prematurity Awareness Month, March of Dimes issues a report card on the state of the health of moms and babies across the U.S.

October 30, 2020

Overview and Frequently Asked Questions on Preterm Birth

Centers for Disease Control and Prevention information hub on preterm birth

April 21, 2020

We Can Do This! Podcast: “Born too soon; the difference a day makes.”

A conversation hosted by National Consumers League Executive Director, Sally Greenberg, with Dr. Joia Adele Crear-Perry of the National Birth Equity Collaborative and Dr. Kelle H. Moley, former Chief Scientific Officer of March of Dimes

Information on 17P

In 2020, the U.S. Food and Drug Administration (FDA) proposed that the only FDA-approved therapy reduce the risk of recurrent preterm birth, hydroxyprogesterone caproate or “17P,” be withdrawn from the market in all forms—including the branded product and five generic versions. This recommendation takes into account conflicting data from two clinical trials with markedly different patient populations: the original approval trial, which included a majority of African American women (59 percent) and women from other minority populations in the United States, and a confirmatory trial that was primarily conducted outside of the United States with a predominantly white population.

October 2020

Makena (hydroxyprogesterone caproate injection)
Information

Fighting to Protect 17P

Food and Drug Administration Docket

The Food and Drug Administration Docket features perspectives of maternal and infant health advocates, clinicians, and families impacted by prematurity. Statements have been posted by leading stakeholder organizations, including Alliance members such as Black Women’s Health Imperative, HealthyWomen, and Sidelines High-Risk Pregnancy Support Network.

June 23, 2021

Note to CDER Director requesting meeting on preterm birth

The PBPA requested a meeting with Director Dr. Cavazzoni to discuss the public health importance of maintaining access to 17P.

June 21, 2021

PBPA statement urging the agency to protect access to 17P and to hold a public hearing

The PBPA submitted a comment to the FDA docket urging the agency to protect patient access to 17P and to grant a public hearing.

May 11, 2021

Letter to Acting Food and Drug Administration Commissioner requesting meeting on preterm birth

The PBPA requested the opportunity to meet with Acting Director Dr. Woodcock to share the concerns of communities affected by preterm birth.

November 25, 2020

Letter to the Food and Drug Administration from 15 members of Congress

Members of Congress urged the FDA to consider stakeholder voices in its decision surrounding whether to withdraw the only FDA-approved treatment for recurrent preterm birth.

October 14, 2020

The FDA must create a win-win path leading to new data on 17P and protect access for pregnant mothers

National Consumers League Executive Director, Sally Greenberg, published a blog post urging the FDA to factor in the experiences of mothers and healthcare providers in its decision regarding 17P.

October 7, 2020

National Consumers League statement urging FDA to make patient-centered decision on only available treatment option for pregnant mothers at risk for recurrent preterm birth

National Consumers League submitted a comment to the FDA docket urging the agency to center patients in its decision regarding potential withdrawal of 17P.

June 30, 2020

NCL leads advocates in urging FDA to protect patient access to critical therapy for preterm birth

National Consumers League issued a press release highlighting a letter sent to the FDA to protect patient access to 17P.

June 18, 2020

Letter urging FDA to protect patient access to critical therapy for preterm birth

National Consumers League led a group of maternal and infant health stakeholders in sending a letter to the FDA urging the agency to maintain patient access to 17P.

Research and FDA Background

  • Role of progestogens in women at risk for spontaneous preterm birth: the final word? (2021)
    Ibrahim SA, Haas DM. Lancet;397:1158-1159.
  • Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth (2020)
    Sibai B, Saade GR, AF Das AF, Gudeman J. J Perinatol.
  • CDER proposes withdrawal of approval for Makena (2020)
    U.S. Food and Drug Administration.
  • Re-examining the Meis Trial for Evidence of False-Positive Results (2020)
    Sibai B, Saade GR, Das AF. Obstet Gynecol;136(3):622-627.
  • 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double- Blind Trial (2019)
    Blackwell SC et al. J Perinatol;37(2):127-136.
  • 4-Year follow-up of children exposed to 17alpha hydroxyprogesterone caproate (17P) in utero (2006)
    Northen A. Am J Obstet Gynecol;195(6,56).
  • Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate (2003)
    Meis PJ et al., N Engl J Med;348:2379-2385.

Contact Us

We’d Like to Hear from You

Please contact us if your organization is interested in learning about our efforts, or sign up to stay up to date on Alliance news and activities.

Melody Merin, Senior Director of Communications
National Consumers League
melodym@nclnet.org

Initial support for the Preterm Birth Prevention Alliance has been provided by Covis Pharma

Scroll to top

[gravityform id=”11″ title=”true” description=”false”]

[gravityform id=”9″ title=”true” description=”false” ajax=”true”]

PBPA Commends HHS Funding to Support Maternal and Infant Health

The Preterm Birth Prevention Alliance (PBPA), a coalition of maternal and women’s health advocates dedicated to improving preterm birth outcomes in the United States and addressing its disproportionate impact on women of color, applauds the U.S. Department of Health and Human Services (HHS) for awarding nearly $350 million to states across the country to improve support for safe pregnancies and healthy babies.

“For far too long, U.S. maternal health care has lagged behind that of other developed countries, particularly for women of color,” noted Sally Greenberg, Executive Director of the National Consumers League. “This additional funding will enable local health departments and nonprofits to better address the health care needs of the most vulnerable mothers and their babies.”

The funding, awarded by HHS’ Health Resources and Services Administration (HRSA), will support home visiting services, increase access to doulas, address infant mortality and maternal illness, and improve data reporting on maternal mortality.

“Maternal health care in the U.S. has consistently failed women of color,” Greenberg continued.  “We applaud HHS for this additional funding that will help to improve the maternal health for all mothers and babies, especially women of color and those most at-risk.”

The funding announcement follows the release of a report by the U.S. Commission on Civil Rights which found that Native American women are more than two times more likely to die from pregnancy-related complications than white women in the U.S. This disparity was further exacerbated for Black women in the U.S., who are three to four times more likely to die from pregnancy-related complications than white women.

“In addition to expanding programs to support maternal health, we must increase representation from racially and ethnically diverse groups in research and clinical trials, particularly those studying treatment options to prevent maternal morbidity and mortality,” said Greenberg.  “The need for the additional HHS funding and the report from the Commission on Civil Rights clearly illustrate how critical representative research and real world evidence are to ensuring all mothers and their babies have the same opportunity for the best possible health outcomes.”

Diverse research for a diverse America: The value of equitable, real-world research

August 12, 2021/in Blog, Health, Prevention Blog Post

By Sally Greenberg, NCL Executive Director

While the COVID-19 pandemic has led to hardship for all Americans, it is clear that people of color have been disproportionately burdened. Across the health care continuum, addressing this disparity has become part of the broader conversation about the history of systemic racism and the underlying social determinants of health that negatively affect the mental, physical, and economic health of individuals and entire communities.

The pandemic has underscored persistent health disparities, and there is growing recognition that representation in research and clinical trials can have a profound impact on health outcomes. A lack of representation from racially and ethnically diverse groups in research and clinical trials have typically led to gaps in data, missing the opportunity to assess the full impact of various treatments and drugs across a range of populations. The collection and use of real-world research and data to inform the potential use, risks, and benefits of medical products and treatments can ultimately lead to better health outcomes, particularly for those who have been underrepresented in the past.

Existing efforts to improve inclusion

Efforts to expand diversity and representation in medical research are underway in Congress. Policymakers are encouraging the incorporation of Real World Evidence (RWE) in drug development through the recent Cures 2.0 draft legislation released by Reps. Diana Degette (D-CO-1) and Fred Upton (D-MI-6). While the status quo limits us from effectively reaching underserved populations, the proposed legislation would allow studies that include RWE for some drugs after they have been approved. At the heart of this issue is a growing appreciation that the same therapy can affect different populations in different ways, which is why Cures 2.0 supports collecting data that more accurately reflects the unique experiences and needs of patients across diverse populations.

Recognizing the potential for RWE in maternal health

The lack of representative research in the field of maternal health is undeniable, and its implications are staggering. The dismal state of maternal care in the United States reflects how our health care system has failed women of color, including by not adequately studying treatment options to prevent maternal morbidity and mortality. The need for RWE is clear when you consider the persistent disparities in health outcomes that plague minority communities.

Preterm birth and its disproportionate impact on women of color is a stark illustration of the need to make progress on representative research in maternal health. Preterm birth is the second-largest contributor to infant death in America today. Despite the tremendous physical, emotional, and financial toll that preterm birth continues to take on our country — disproportionately so on women and families of color — not enough therapeutic tools currently exist to prevent it.

Today, “17P,” the only FDA-approved treatment to help reduce the likelihood of spontaneous, recurrent preterm birth in the United States is at-risk of being withdrawn from the market in all its forms, including the branded product and five generic versions. Unfortunately there is conflicting evidence from two different clinical trials, one representative of a diverse U.S. population and another studied in a largely white population in Europe. It’s not a straightforward comparison. If 17P is withdrawn, the women most affected by preterm birth, predominantly women of color, would be left without an FDA-approved treatment option.

The FDA is considering the path forward, including additional data collection through leveraging RWE from past patient use. The success of the first (approval) trial for 17P in the impacted communities signals the importance of RWE. Continued access to 17P is, at its core, a matter of health equity. Black women must not yet again be left vulnerable to a system that historically has overlooked them.

PRETERM BIRTH PREVENTION ALLIANCE APPLAUDS FDA’S GRANTING OF HEARING FOR THE ONLY FDA-APPROVED THERAPIES TO REDUCE RECURRENT PRETERM BIRTH

WASHINGTON, DC, August 26, 2021 –

Preterm Birth Prevention Alliance a coalition of maternal and women’s health advocates dedicated to improving preterm birth outcomes in the United States and addressing its disproportionate impact on women of color, commends the U.S. Food and Drug Administration (FDA) for granting a public hearing to discuss 17P, the only FDA-approved class of branded and generic treatments to reduce preterm birth in indicated patients.

We appreciate the FDA’s willingness to hear directly from individuals facing prematurity and the providers who treat them about their experiences with 17P,” said National Consumer League’s Executive Director Sally Greenberg. “It is an important step towards better understanding variations in efficacy across diverse populations and ensuring all women have an equal chance at the best possible outcomes.”

Last week, the FDA agreed to grant Covis Pharma, the manufacturer of the branded 17P product Makena its request for a public hearing to discuss 17P. Hydroxyprogesterone caproate—or “17P”—has been approved since 2011 and is the only FDA-approved class of treatments to help prevent spontaneous, recurrent preterm birth in the United States. In 2020, the FDA proposed withdrawing 17P in all its forms, including the branded product and its five generic versions, based on conflicting efficacy data from two studies composed of vastly different populations, one predominantly inclusive of women in the U.S. most vulnerable to preterm birth and one not.

“Mothers and birthing people deserve access to the best possible treatments to prevent preterm birth. We cannot achieve birth equity if we study pregnant women as a monolith,” said Blythe Thomas, Initiative Director of 1,000 Days. “It is only by systematically researching the real-world, post-market impact of 17P on individuals from a variety of racial and ethnic backgrounds, while maintaining access for all affected, that we can reduce disparities in maternal and infant health.”

While the hearing date has not yet been set, the Alliance looks forward to sharing the perspectives of affected individuals and their physicians with the agency once the hearing is scheduled and will continue to advocate for at-risk moms and babies of all races and ethnicities.

###

ABOUT THE PRETERM BIRTH PREVENTION ALLIANCE

The Preterm Birth Prevention Alliance (PBPA) is a coalition of maternal and women’s health advocates who share a common concern about the state of preterm birth in the United States and the proposed market withdrawal of 17P, the only FDA-approved class of treatments to help prevent spontaneous, recurrent preterm birth. Formed in 2021 by the National Consumers League, the 15 partners in the PBPA seek to improve preterm birth outcomes in the United States by maintaining access to safe, FDA-approved treatment options and advocating for more diverse medical research that adequately represents the experiences of women and newborns of color. Women of color need a seat at the table. To learn more, visit www.pretermbirthalliance.org

LEADING PATIENT ADVOCATES LAUNCH PRETERM BIRTH PREVENTION ALLIANCE TO PROTECT CRITICAL ACCESS TO THE SOLE FDA-APPROVED CLASS OF THERAPIES TO REDUCE RECURRENT PRETERM BIRTH

WASHINGTON, DC, April 20, 2021 – Today, the National Consumers League (NCL), along with a coalition of patient advocacy organizations dedicated to advancing the health of mothers and infants, announced the launch of the >Preterm Birth Prevention Alliance.

Members of the Alliance are joining forces in an effort to preserve patient access to the only Food & Drug Administration-approved class of treatments for pregnant women who have previously had an unexpected, or spontaneous, preterm birth. Together, Alliance members seek to ensure that the Food & Drug Administration (FDA) hears concerns from the full range of stakeholders about the potential risks and impact of withdrawal for at-risk pregnant women and their providers.

For the fifth year in a row, the U.S. preterm birth rate has increased (to 10.2 percent of births), and preterm birth and its complications were the second largest contributor to infant death across the country. Preterm birth also represents a significant racial health disparity, with Black women in America experiencing premature delivery at a rate 50 percent higher than other racial groups throughout the country.

However, in 2020, the FDA >proposed withdrawing hydroxyprogesterone caproate, commonly called “17P” or “17-OHPC”, the only FDA-approved class of branded and generic treatments to help prevent the risk of preterm birth in women with a history of spontaneous preterm birth. The FDA is currently determining whether to hold a hearing on the status of 17P, based on conflicting efficacy data from two studies composed of vastly different patient populations, one inclusive of women in the U.S. most vulnerable to preterm birth and one not.

“We’re fighting for a more inclusive healthcare system that gives everyone an equal chance to have the best outcomes possible,” said Sally Greenberg, executive director of the National Consumers League. “We don’t believe that removing 17P from the market without gaining a better understanding of who could benefit the most from its use is in the best interests of patients, nor their healthcare providers, particularly as there are no other approved treatment options available.”

To date, 14 organizations have joined NCL to advocate for the health interests of at-risk pregnant women and infants, including: 1,000 Days; 2020 Mom; American Association of Birth Centers; Black Mamas Matter Alliance; Black Women’s Health Imperative; Expecting Health; Healthy Mothers, Healthy Babies Montana; HealthyWomen; Miracle Babies; National Birth Equity Collaborative; National Black Midwives Alliance; National Partnership for Women & Families; Sidelines High-Risk National Support Network; and SisterReach.

“As a trained obstetrician and gynecologist, I know firsthand the impact of preterm birth on Black women and birthing people. I also know that racism – not race – is the driving factor leading the disproportionate impact of preterm birth on Black women and birthing people thereby exacerbating systemic inequities in maternal and infant health. To achieve birth equity, which is the assurance of the conditions of optimal births for all people with a willingness to address racial and social inequities in a sustained effort, we must work to protect and uphold a standard of care for spontaneous, recurrent preterm births and ensure it remains accessible and affordable for all who stand in need,” added Dr. Joia Crear Perry, founder and president of the National Birth Equity Collaborative.

The Preterm Birth Prevention Alliance is calling for the FDA to grant a public hearing to fully consider all of the data, additional research methods, and stakeholder perspectives before deciding whether to withdraw approval of this critical class of therapies. The health of America’s moms and babies warrants the utmost care and consideration.

###

ABOUT THE PRETERM BIRTH PREVENTION ALLIANCE

The Preterm Birth Prevention Alliance is a coalition of maternal and women’s health advocates who share a common concern about the state of preterm birth in the United States and the proposed market withdrawal of 17P, the only FDA-approved class of treatments to help prevent spontaneous, recurrent preterm birth. Formed in 2021 by the National Consumers League, we seek to improve preterm birth outcomes in the United States by maintaining access to safe, FDA-approved treatment options and advocating for more diverse medical research that adequately represents the experiences of women and newborns of color. Women of color need a seat at the table. To learn more, visit www.pretermbirthalliance.org.

Initial support for the Preterm Birth Prevention Alliance is provided by Covis Pharma.

MEDIA CONTACT:

Carol McKay, carolm@nclnet.org

<embed src=”https://art19.com/shows/ce489618-5918-423a-9b5f-35ce4c28ca09/episodes/2f8fa6fc-6aad-4f1f-bf13-3bdb0aa41732/embed?theme=light-custom&primary_color=%231850a3″ width=”100%” height=”300″></embed>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/c7b22520-c0aa-4718-9b59-4ee67e494547/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/ab80228e-48d9-4a45-a894-a1bfc4e41c64/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/ea08cbc0-f9f2-4082-9222-4e33f68b6826/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/5039453f-6008-413a-9f6b-c9be649fd26e/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/fafb46f8-6d90-4cd8-91be-616366d1b8ca/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/25f0485d-bbce-46c8-bb90-139dcf1a2e7b/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/ffbcae35-84c5-4c8b-9686-6e2c79679dd0/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/520bdd73-d142-4508-9706-d81b5c042dff/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/12354e8b-bf15-4eba-b34f-20e435df3bb7/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>

<iframe src=”https://art19.com/shows/we-can-do-this/episodes/e2091efc-d66d-49f4-aa8e-8e6249858310/embed?theme=light-custom” style=”width: 100%; height: 200px; border: 0 none;” scrolling=”no”></iframe>